PB-28 is an agonist of the sigma-2 receptor.
It is derived from cyclohexylpiperazine.
Usage Research and oncology
In oncology, it has been noted that PB-28 reverts doxorubicin resistance of breast cancer cells by supplementing Oxygen () receptor binding.Francesco Berardi, Carmen Abate, Savina Ferorelli, Vincenzo Uricchio, Nicola A. Colabufo, Mauro Niso, Roberto Perrone; Exploring the Importance of Piperazine N-Atoms for σ2 Receptor Affinity and Activity in a Series of Analogs of 1-Cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (PB28)†. J. Med. Chem. 10 December 2009; 52 (23): 7817–7828. https://doi.org/10.1021/jm9007505
References
External links